TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18367613
Drug: Chronic prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic prednisone treatment (7.5 +/- 0.8 mg)
Study: 18367613
Drug: Acute prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute prednisone administration 1 hour before retention testing
Study: 9176834
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zinc
Study: 9176834
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zinc with micronutrients
Study: 9176834
Drug: Zinc-containing treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-containing treatments
Study: 2481787
Drug: Mepindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol (10 mg/day)
Study: 2481787
Drug: Celiprolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (400 mg/day)
Study: 25795285
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (2.5 g twice daily)
Study: 19201289
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic Lactobacillus rhamnosus R0011 strain (500 million active cells/tablet twice daily)
Study: 17317362
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day of atorvastatin for 16 weeks
Study: 28886437
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg apple polyphenols (AE)
Study: 28886437
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg apple polyphenols + 600 mg blackcurrant anthocyanins (AE+BE)
Study: 26635453
Drug: Topical 0.02%
Normalized name: tretinoin topical 0.02% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.02% mitomycin C four times a day for five days
Study: 26635453
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% cyclosporine four times a day for three months
Study: 26635453
Drug: Topical 2.5%
Normalized name: menthol topical 2.5% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2.5% bevacizumab four times a day for three months
Study: 23466591
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate 5 g daily
Study: 17056383
Drug: Subconjunctival lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival lidocaine 2% injection
Study: 10867305
Drug: Immediate, rent-free,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate, rent-free, abstinent-contingent housing during a 2-month Behavioral Day Treatment program
Study: 10867305
Drug: Behavioral Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Day Treatment attendance
Study: 1703237
Drug: Flavone acetic
Normalized name: flavone
DrugBank: Flavone (DB07776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavone acetic acid at doses less than or equal to 3.9 g/m2 administered intravenously over 1 hour
Study: 1703237
Drug: Flavone acetic
Normalized name: flavone
DrugBank: Flavone (DB07776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavone acetic acid at doses greater than or equal to 5.28 g/m2 administered over 6 hours
Study: 1703237
Drug: Flavone acetic
Normalized name: flavone
DrugBank: Flavone (DB07776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavone acetic acid at 10 g/m2
Study: 1703237
Drug: Flavone acetic
Normalized name: flavone
DrugBank: Flavone (DB07776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavone acetic acid at 8 g/m2 recommended for phase II
Study: 6867755
Drug: Sequential MTX/5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential MTX/5‐FU
Study: 6867755
Drug: Sequential 5‐FU/MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential 5‐FU/MTX
Study: 26813483
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behavioral therapy (CBT) delivered via email, 10 to 12 sessions conducted by a psychiatrist and a psychiatry resident.
Study: 24352960
Drug: DDGS at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDGS at 0.5% of BW daily (DM basis)
Study: 24352960
Drug: DDGS at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDGS at 1% of BW daily (DM basis)
Study: 21978965
Drug: Celivarone 300
Normalized name: Celivarone
DrugBank: Celivarone (DB16012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celivarone 300 mg once daily for 6 months
Study: 21978965
Drug: Celivarone 300
Normalized name: Celivarone
DrugBank: Celivarone (DB16012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celivarone 300 mg once daily for 6 months (subgroup analysis)
Study: 20451927
Drug: Pramipexole 0.25-0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.25-0.75 mg/day
Study: 18046434
Drug: Perindopril (ACE-inhibitor)
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril (ACE-inhibitor)
Study: 12444517
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment (15 days strapping plus early controlled mobilization)
Study: 2344111
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient treatment program
Study: 2344111
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient treatment program (after crossover)
Study: 6424491
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate aerosol (2 mg four times daily)
Study: 6424491
Drug: Conventional powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional powder (20 mg four times daily by Spinhaler)
Study: 28872672
Drug: Business as
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Business as usual treatment
Study: 29950252
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate 10 mg once weekly for eight weeks
Study: 29950252
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids 40 mg daily for eight weeks, then tapered
Study: 24092823
Drug: Preoperative octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative octreotide treatment (n=28)
Study: 24092823
Drug: Octreotide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide treatment for 6 months
Study: 17882161
Drug: Laropiprant (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laropiprant (single doses up to 900 mg)
Study: 17882161
Drug: Laropiprant (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laropiprant (multiple doses up to 450 mg)
Study: 17882161
Drug: Laropiprant (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laropiprant (single doses of 6 mg and higher)
Study: 17882161
Drug: Laropiprant (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laropiprant (multiple doses up to 200 mg)
Study: 10440427
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg tablet)
Study: 10440427
Drug: Theophylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300 mg capsule)
Study: 8680375
Drug: Inhaled bradykinin
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bradykinin (8 mg.mL‐1)
Study: 8680375
Drug: Inhaled [desArg9]-bradykinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled [desArg9]-bradykinin (8 mg.mL‐1)
Study: 26842107
Drug: Mirtazapine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (starting at 15 mg daily for 2 weeks, increasing to 30 mg daily thereafter, for up to 12 months)
Study: 30736951
Drug: Moxidectin (MXD)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MXD) 0.2 mg/kg SC
Study: 30736951
Drug: Moxidectin (MXD)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MXD) 1.0 mg/kg SC
Study: 30736951
Drug: Moxidectin (MXD)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MXD) 0.2 mg/kg IR
Study: 30736951
Drug: Moxidectin (MXD)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MXD) 1.0 mg/kg IR
Study: 30736951
Drug: Ivermectin (IVM)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin (IVM) 0.2 mg/kg SC
Study: 20191820
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) therapy
Study: 16669847
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg twice daily for 5 days)
Study: 16669847
Drug: Diltiazem (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (100 mg twice daily for 5 days)
Study: 12525736
Drug: Thalidomide (TL)
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide (TL) at doses up to 200 mg/d
Study: 1425819
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with bromocriptine and levodopa
Study: 3939673
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg bid)
Study: 22652593
Drug: G-CSF 10
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 10 μg/kg per day intravenously for 5 consecutive days
Study: 22652593
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar treatments without G-CSF)
Study: 20028939
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diazoxide at bedtime
Study: 18541589
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (3 g CaCO3 daily, providing 1200 mg elemental Ca)
Study: 11032056
Drug: Dithranol cream
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol cream
Study: 8421798
Drug: DDAVP infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP infusion (0.3 microliter per kilogram) during 15 to 30 minutes within one hour of anesthetic induction
Study: 2430084
Drug: 7S immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7S immunoglobulin G (400 mg IgG/kg body weight over 5 days)
Study: 2430084
Drug: 5S immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5S immunoglobulin G (400 mg IgG/kg body weight over 5 days)
Study: 18417741
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 10,000 IU once weekly
Study: 16184544
Drug: Basiliximab 20
Normalized name: basiliximab 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab 20 mg on days 0 and 4; tacrolimus delayed until renal function improved
Study: 25190617
Drug: Tailored duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored duration of ECS therapy following an initial therapeutic period of 6 months
Study: 25190617
Drug: Standard duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard duration of ECS therapy for 24 months
Study: 22242967
Drug: Febuxostat 120
Normalized name: Febuxostat 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 120 mg daily for 9 days (regimen A)
Study: 19464001
Drug: P(4) +
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P(4) + oral E(2) valerate
Study: 7953888
Drug: G‐CSF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF and Gm‐CSF
Study: 29154814
Drug: Aquarobic exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquarobic exercise and burdock intake combination
Study: 14504313
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with PE followed by IVIg or immunoabsorption followed by IVIg
Study: 24355450
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (monthly videoconferences with a nurse for 32 weeks)
Study: 22335087
Drug: Height and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Height and weight adjusted dose of intrathecal hyperbaric bupivacaine (Group AD)
Study: 22335087
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of intrathecal hyperbaric bupivacaine (2.2 ml) (Group FD)
Study: 22335087
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of intrathecal hyperbaric bupivacaine (Group FD)
Study: 16895948
Drug: Perioperative hyperinsulinemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative hyperinsulinemic normoglycemic clamp (regular insulin at a fixed rate of 0.1 IU.kg(‐1).h(‐1)) during 26 hours
Study: 14745701
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of ill index cases with oseltamivir for 5 days (n=402)
Study: 11355938
Drug: CA 125
Normalized name: ACA 125
DrugBank: ACA 125 (DB05489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 125 monitoring during first-line chemotherapy
Study: 8133020
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g DGLA
Study: 8133020
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g safflower oil
Study: 23347793
Drug: pegaptanib injection
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegaptanib injection
Study: 21629200
Drug: Liquid L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid L-carnitine (50 mg L-carnitine/kg bodyweight/day) for 3 months
Study: 20144362
Drug: Levemir (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levemir (insulin detemir) FlexPen
Study: 20144362
Drug: OptiClik (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiClik (insulin glargine)
Study: 17723076
Drug: S-albuterol 5
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-albuterol 5 mg
Study: 11682440
Drug: L-NMMA (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (16 micromol min(‐1))
Study: 11682440
Drug: L-NMMA (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (64 micromol min(‐1))
Study: 9702445
Drug: Lisinopril (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (average of 15 mg daily)
Study: 8081665
Drug: methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone (MP) treatment
Study: 2644918
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (details on dosage and duration not specified)
Study: 31778442
Drug: Liposomal lidocaine/prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal lidocaine/prilocaine gel
Study: 25259546
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg a.m.
Study: 25259546
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg p.m.
Study: 25259546
Drug: Lisinopril 40
Normalized name: lisinopril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 40 mg a.m.
Study: 23596347
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl wafer
Study: 12637196
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) 600 IU daily
Study: 3544640
Drug: Aminophylline (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (4.5 mg/kg)
Study: 3544640
Drug: Enprofylline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (1.5 mg/kg)
Study: 26797633
Drug: L-theanine-based nutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine-based nutrient drink
Study: 23357971
Drug: Gemcitabine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (dose >17,000 mg/m)
Study: 23357971
Drug: Gemcitabine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (dose >15,000 mg/m)
Study: 20001434
Drug: Tadalafil 40
Normalized name: tadalafil 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 40 mg once daily
Study: 17284745
Drug: High-folate diet
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-folate diet with 369 mug food folate/d and a placebo capsule (Group A)
Study: 17284745
Drug: Low-folate diet
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group B, 92 microg folic acid/d)
Study: 17284745
Drug: Low-folate diet
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group C, 191 microg folic acid/d)
Study: 17284745
Drug: Low-folate diet
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group D, 289 microg folic acid/d)
Study: 14748940
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C (500 mg/d)
Study: 14748940
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin C (50 mg/d)
Study: 10209562
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at doses of 0.05, 0.10, or 0.20 lU/kg/day
Study: 7933500
Drug: Inhalation anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthetics (sevoflurane, isoflurane, halothane) with oxygen and nitrous oxide
Study: 7933500
Drug: Postoperative analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesics (diclofenac, acetaminophen suppositories, intravenous pentazocine)
Study: 3124046
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir daily for one year
Study: 3124046
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir during outbreaks of herpes
Study: 27714799
Drug: Stand-alone prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stand-alone prescription drug plan (PDP)
Study: 27714799
Drug: Medicare Advantage
Normalized name: Advantage Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicare Advantage plan with prescription drug coverage (MA-PD)
Study: 23948440
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral multivitamin supplementation (vitamin B complex, C and E) for 24 months
Study: 21125461
Drug: Clazosentan 1
Normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clazosentan 1 mg/h
Study: 18196636
Drug: Thyroliberin 500
Normalized name: Thyroliberin
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thyroliberin 500 mcg twice a day for 5 days
Study: 14730113
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg of Zn2+ once daily)
Study: 1438004
Drug: Flurbiprofen in
Normalized name: Product containing flurbiprofen in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen in the fed state (with water 15 min after 330 ml of apple juice)
Study: 4084483
Drug: Bromocriptine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine with prior metoclopramide treatment
Study: 29533491
Drug: High-dose hemoporfin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hemoporfin (5 mg/kg)
Study: 29533491
Drug: Low-dose hemoporfin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hemoporfin (2.5 mg/kg)
Study: 27501207
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with routine antiemetic therapy only
Study: 23283457
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy of dapsone and rifampicin
Study: 18341562
Drug: Xylitol lozenges
Normalized name: xylitol Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol lozenges (2.5 g xylitol, 3 times a day)
Study: 18341562
Drug: Xylitol/fluoride lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol/fluoride lozenges (1.5 mg fluoride, 3 times a day)
Study: 18341562
Drug: Reference no-tablet
Normalized name: caffeine Oral Tablet [No Doz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference no-tablet group (n = 70)
Study: 12215081
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (MMTP only)
Study: 7482648
Drug: BY963 (spherosome
Approvals — FDA: no, EMA: no, PMDA: no
Description: BY963 (spherosome suspension containing a phospholipid), administered in three doses (2.5, 5, and 10 mL) at four different injection rates (0.25, 0.5, and 1 mL/s and bolus)
Study: 7482648
Drug: BY963 (spherosome
Approvals — FDA: no, EMA: no, PMDA: no
Description: BY963 (spherosome suspension containing a phospholipid)
Study: 30276532
Drug: PH1-Cons (under
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH1-Cons (under conservative treatment)
Study: 24976429
Drug: Aged black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged black garlic (ABG), 6 g/d, twice daily for 12 weeks
Study: 17950791
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus planned glycoprotein IIb/IIIa inhibitor (GPI)
Study: 16343666
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (Aspirin)
Study: 16343666
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (Warfarin)